Acadian Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $117M | Sell |
151,191
-294,604
| -66% | -$226M | 0.17% | 134 |
|
|
2025
Q4 | $344M | Sell |
445,795
-138,710
| -24% | -$94.2M | 0.56% | 42 |
|
|
2025
Q3 | $329M | Buy |
584,505
+118,765
| +26% | +$67.2M | 0.57% | 44 |
|
|
2025
Q2 | $244M | Buy |
465,740
+326,583
| +235% | +$182M | 0.5% | 53 |
|
|
2025
Q1 | $88.2M | Buy |
139,157
+56,816
| +69% | +$39.1M | 0.25% | 90 |
|
|
2024
Q4 | $58.6M | Buy |
82,341
+15,052
| +22% | +$12.6M | 0.17% | 131 |
|
|
2024
Q3 | $70.7M | Sell |
67,289
-5,541
| -8% | -$6.17M | 0.22% | 122 |
|
|
2024
Q2 | $76.5M | Buy |
72,830
+10,689
| +17% | +$10.4M | 0.24% | 103 |
|
|
2024
Q1 | $59.8M | Buy |
62,141
+16,856
| +37% | +$16M | 0.21% | 119 |
|
|
2023
Q4 | $39.7M | Sell |
45,285
-26,007
| -36% | -$21.4M | 0.15% | 140 |
|
|
2023
Q3 | $58.6M | Sell |
71,292
-10,784
| -13% | -$8.48M | 0.25% | 112 |
|
|
2023
Q2 | $58.9M | Sell |
82,076
-20,953
| -20% | -$16.2M | 0.24% | 117 |
|
|
2023
Q1 | $84.6M | Sell |
103,029
-97,354
| -49% | -$73.4M | 0.37% | 83 |
|
|
2022
Q4 | $145M | Sell |
200,383
-60,612
| -23% | -$44.7M | 0.71% | 27 |
|
|
2022
Q3 | $180M | Sell |
260,995
-98,420
| -27% | -$61.9M | 0.98% | 13 |
|
|
2022
Q2 | $212M | Sell |
359,415
-69,783
| -16% | -$45.4M | 1.09% | 12 |
|
|
2022
Q1 | $300M | Sell |
429,198
-22,995
| -5% | -$14.5M | 1.24% | 9 |
|
|
2021
Q4 | $286M | Sell |
452,193
-77,272
| -15% | -$47.5M | 1.07% | 13 |
|
|
2021
Q3 | $320M | Buy |
529,465
+87,815
| +20% | +$54.5M | 1.22% | 11 |
|
|
2021
Q2 | $247M | Buy |
441,650
+16,276
| +4% | +$8.25M | 0.93% | 15 |
|
|
2021
Q1 | $201M | Buy |
425,374
+331,154
| +351% | +$161M | 0.78% | 21 |
|
|
2020
Q4 | $45.5M | Sell |
94,220
-1,279
| -1% | -$690K | 0.18% | 115 |
|
|
2020
Q3 | $53.5M | Buy |
95,499
+15,280
| +19% | +$9.26M | 0.22% | 100 |
|
|
2020
Q2 | $50M | Buy |
80,219
+76,654
| +2,150% | +$43.5M | 0.22% | 117 |
|
|
2020
Q1 | $1.74M | Buy |
3,565
+1,638
| +85% | +$676K | 0.01% | 645 |
|
|
2019
Q4 | $724K | Buy |
1,927
+1,004
| +109% | +$338K | ﹤0.01% | 971 |
|
|
2019
Q3 | $256K | Sell |
923
-1,065
| -54% | -$315K | ﹤0.01% | 1259 |
|
|
2019
Q2 | $622K | Sell |
1,988
-2,836
| -59% | -$944K | ﹤0.01% | 942 |
|
|
2019
Q1 | $1.98M | Sell |
4,824
-18,790
| -80% | -$7.74M | 0.01% | 697 |
|
|
2018
Q4 | $8.82M | Buy |
23,614
+2,479
| +12% | +$907K | 0.04% | 284 |
|
|
2018
Q3 | $8.54M | Buy |
21,135
+19,649
| +1,322% | +$7.48M | 0.04% | 304 |
|
|
2018
Q2 | $513K | Buy |
+1,486
| New | +$465K | ﹤0.01% | 888 |
|
|
2018
Q1 | – | Sell |
-202
| Closed | -$76K | – | 1806 |
|
|
2017
Q4 | $76K | Sell |
202
-262
| -56% | -$106K | ﹤0.01% | 1155 |
|
|
2017
Q3 | $208K | Sell |
464
-1,032
| -69% | -$491K | ﹤0.01% | 907 |
|
|
2017
Q2 | $735K | Buy |
1,496
+1,429
| +2,133% | +$625K | ﹤0.01% | 755 |
|
|
2017
Q1 | $26K | Sell |
67
-151
| -69% | -$56K | ﹤0.01% | 1331 |
|
|
2016
Q4 | $81K | Sell |
218
-516
| -70% | -$196K | ﹤0.01% | 1123 |
|
|
2016
Q3 | $295K | Sell |
734
-1,149
| -61% | -$461K | ﹤0.01% | 910 |
|
|
2016
Q2 | $657K | Buy |
1,883
+1,164
| +162% | +$448K | ﹤0.01% | 713 |
|
|
2016
Q1 | $259K | Hold |
719
| – | – | ﹤0.01% | 866 |
|
|
2015
Q4 | $390K | Hold |
719
| – | – | ﹤0.01% | 849 |
|
|
2015
Q3 | $334K | Hold |
719
| – | – | ﹤0.01% | 829 |
|
|
2015
Q2 | $367K | Sell |
719
-191
| -21% | -$93.2K | ﹤0.01% | 836 |
|
|
2015
Q1 | $411K | Hold |
910
| – | – | ﹤0.01% | 806 |
|
|
2014
Q4 | $373K | Buy |
+910
| New | +$358K | ﹤0.01% | 812 |
|
Other funds holding REGN
VCM
N
Acadian Asset Management's REGN Position: Q1 2026 in Review
Acadian Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 66% in Q1 2026, selling an estimated $226M and leaving 151,191 shares worth $117M. The position accounts for 0.17% of the portfolio, ranked #134.
Acadian Asset Management first reported a position in REGN in Q4 2014 and has held it in 45 quarters since. The position peaked at $344M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Acadian Asset Management held 151,191 shares of Regeneron Pharmaceuticals worth $117M as of Q1 2026.
- Acadian Asset Management sold 294,604 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $226M.
- Regeneron Pharmaceuticals made up 0.17% of Acadian Asset Management's portfolio in Q1 2026, its #134 holding.
- Acadian Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
- Acadian Asset Management's Regeneron Pharmaceuticals position peaked at $344M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.